A Study to Evaluate Lung Ultrasound as a Method to Measure Changes in Extravascular Lung Water Induced by Positional Changes (LUPE)

Status:	Recruiting
Conditions:	Cardiology
Therapuetic Areas:	Cardiology / Vascular Diseases
Healthy:	No
Age Range:	21 - Any
Updated:	7/21/2018
Start Date:	May 4, 2017
End Date:	November 2019
Contact:	kimberly clinton
Email:	kimberly.clinton@uphs.upenn.edu
Phone:	215-662-2803

A Study to Evaluate Lung Ultrasound as a Method to Measure Changes in Extravascular Lung Water Induced by Positional Changes or Exercise in Patients Stabilized Following Hospitalization for Acute Decompensated Heart Failure

This is an exploratory study to evaluate lung ultrasound as a method for measuring
extravascular lung water in stabilized patients during hospitalization for ADHF. Subjects who
have been stabilized following admission for ADHF and capable of lying supine will be
evaluated by lung ultrasound to determine the degree of lung congestion as measured by the
total B-line score. Since different patients may require different degrees of postural change
and/or other maneuvers (e.g., leg elevation or exercise) to induce B-line increments, a
tailored sequential protocol will be employed to define which maneuvers are sufficient for
each patient.

Inclusion Criteria:

Hospitalized for the management of acute decompensated heart failure

Reached at least a 12-hour period after hospital admission

Presence of peripheral edema with a score of at least 1+ (slight pitting in both ankles;
2mm or less depression that disappears rapidly)

Able to lie supine with no more than one pillow (approximately a 10 cm head elevation)
without dyspnea for at least 30 minutes by patient report

Have not received treatment with any intravenous loop diuretic within the 4 hours prior to
initiating study assessments and with no plans for additional intravenous treatment during
the series of lung ultrasound measurements

Exclusion Criteria:

Persistent uncontrolled hypertension (resting systolic blood pressure > 160 mmHg)

Significant lung disease including severe chronic obstructive pulmonary disease (See
concomitant medication exclusions), pulmonary fibrosis, active asthma or acute pneumonia

Use of medications specified for the treatment of COPD including short- and long-acting
bronchodilators (β-agonists and anticholinergics) and inhaled glucocorticoids as well as
oxygen therapy

Use of another investigational product in a clinical study within the following time period
prior to the first administration of study medication: 30 days, 5 half-lives or twice the
duration of the biological effect of the investigational product (whichever is longer)

We found this trial at

sites

The Mayo Clinic

Rochester, Minnesota 55905

Principal Investigator: Suraj Kapa, MD

Phone: 507-293-2762

from

Rochester, MN